Clinical trial
Web basEd soCial Media tecHnology to Improvement in Adherence to Dual anTiplatelet Therapy Following Drug-Eluting Stent Implantation (WeChat), a Randomized Controlled Branch on Antiplatelet of RESCIND Study
NCT03732066 is registered in ClinicalTrials.gov with Guangdong Provincial People's Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Web basEd soCial Media tecHnology to Improvement in Adherence to Dual anTiplatelet Therapy Following Drug-Eluting Stent Implantation (WeChat), a Randomized Controlled Branch on Antiplatelet of RESCIND Study
- Lead sponsor
- Guangdong Provincial People's Hospital
- Phase
- Not applicable
- Overall status
- Unknown status
- Start date
- January 14, 2019
- Completion date
- September 30, 2021
- Enrollment
- 760 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.